These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 15794203)

  • 21. Systemic therapy with cyclophosphamide and anti-CD20 antibody (rituximab) in relapsed primary cutaneous B-cell lymphoma: a report of 7 cases.
    Fierro MT; Savoia P; Quaglino P; Novelli M; Barberis M; Bernengo MG
    J Am Acad Dermatol; 2003 Aug; 49(2):281-7. PubMed ID: 12894078
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Failure of rituximab to treat a lupus flare-up with nephritis.
    Lambotte O; Dürbach A; Kotb R; Ferlicot S; Delfraissy JF; Goujard C
    Clin Nephrol; 2005 Jul; 64(1):73-7. PubMed ID: 16047649
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of combined cyclophosphamide and rituximab treatment in recalcitrant childhood lupus.
    Ale'ed A; Alsonbul A; Al-Mayouf SM
    Rheumatol Int; 2014 Apr; 34(4):529-33. PubMed ID: 24218286
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment options for proliferative lupus nephritis: an update of clinical trial evidence.
    Navaneethan SD; Viswanathan G; Strippoli GF
    Drugs; 2008; 68(15):2095-104. PubMed ID: 18840001
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis.
    Grootscholten C; Bajema IM; Florquin S; Steenbergen EJ; Peutz-Kootstra CJ; Goldschmeding R; Bijl M; Hagen EC; Van Houwelingen HC; Derksen RH; Berden JH;
    Arthritis Rheum; 2007 Mar; 56(3):924-37. PubMed ID: 17328070
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Lupus-nephritis--diagnosis and treatment].
    Norby GE; Lerang K; Holdaas H; Gran JT; Strøm EH; Draganov B; Os I; Hartmann A; Gilboe IM
    Tidsskr Nor Laegeforen; 2010 Jun; 130(11):1140-4. PubMed ID: 20531500
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study.
    Vigna-Perez M; Hernández-Castro B; Paredes-Saharopulos O; Portales-Pérez D; Baranda L; Abud-Mendoza C; González-Amaro R
    Arthritis Res Ther; 2006; 8(3):R83. PubMed ID: 16677395
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction and maintenance therapy in proliferative lupus nephritis.
    Ponticelli C; Glassock RJ; Moroni G
    J Nephrol; 2010; 23(1):9-16. PubMed ID: 20091481
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Repeated renal biopsy in proliferative lupus nephritis--predictive role of serum C1q and albuminuria.
    Gunnarsson I; Sundelin B; Heimbürger M; Forslid J; van Vollenhoven R; Lundberg I; Jacobson SH
    J Rheumatol; 2002 Apr; 29(4):693-9. PubMed ID: 11950009
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lupus nephritis: where are we now?
    Lightstone L
    Curr Opin Rheumatol; 2010 May; 22(3):252-6. PubMed ID: 20305561
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravenous pulse cyclophosphamide treatment of severe lupus nephritis: a prospective five-year study.
    Valeri A; Radhakrishnan J; Estes D; D'Agati V; Kopelman R; Pernis A; Flis R; Pirani C; Appel GB
    Clin Nephrol; 1994 Aug; 42(2):71-8. PubMed ID: 7955581
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Treatment of systemic lupus erythematosus: myths, certainties and doubts].
    Ruiz-Irastorza G; Danza A; Khamashta M
    Med Clin (Barc); 2013 Dec; 141(12):533-42. PubMed ID: 23622892
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.
    Lindholm C; Börjesson-Asp K; Zendjanchi K; Sundqvist AC; Tarkowski A; Bokarewa M
    J Rheumatol; 2008 May; 35(5):826-33. PubMed ID: 18398943
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of Belimumab for active lupus nephritis in a young Hispanic woman intolerant to standard treatment: a case report.
    Fontana F; Alfano G; Leonelli M; Cerami C; Ligabue G; Spinella A; Citriniti G; Manzini CU; Ferri C; Cappelli G
    BMC Nephrol; 2018 Oct; 19(1):276. PubMed ID: 30342482
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SLE-associated transverse myelitis successfully treated with Rituximab (anti-CD20 monoclonal antibody).
    Armstrong DJ; McCarron MT; Wright GD
    Rheumatol Int; 2006 Jun; 26(8):771-2. PubMed ID: 16231119
    [No Abstract]   [Full Text] [Related]  

  • 36. Severity of systemic lupus erythematosus with diffuse proliferative glomerulonephritis and the ineffectiveness of standard pulse intravenous cyclophosphamide therapy in Jamaican patients.
    Williams W; Bhagwandass A; Sargeant LA; Shah D
    Lupus; 2003; 12(8):640-5. PubMed ID: 12945726
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rituximab in childhood systemic lupus erythematosus refractory to conventional immunosuppression: case report.
    Edelbauer M; Jungraithmayr T; Zimmerhackl LB
    Pediatr Nephrol; 2005 Jun; 20(6):811-3. PubMed ID: 15772840
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Allergo-immunology. Clinical immunology].
    Chizzolini C
    Rev Med Suisse; 2012 Jan; 8(323):11-3. PubMed ID: 22303732
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids.
    Pepper R; Griffith M; Kirwan C; Levy J; Taube D; Pusey C; Lightstone L; Cairns T
    Nephrol Dial Transplant; 2009 Dec; 24(12):3717-23. PubMed ID: 19617257
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exploring new territory: the move towards individualised treatment.
    Haubitz M
    Lupus; 2007; 16(3):227-31. PubMed ID: 17432112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.